Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  van Eupen, Marcelle G A ^a   Schram, Miranda T ^a   Colhoun, Helen M ^b   Scheijen, Jean L J M ^a   Stehouwer, Coen D A ^a   Schalkwijk, Casper G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Advanced glycation endproducts; Coronary artery calcification; Type 1 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(EPSILON) (CARBOXYETHYL) LYSINE; N(EPSILON) (CARBOXYMETHYL)LYSINE; PENTOSIDINE; TETRAHYDROPYRIMIDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; ELECTRON BEAM TOMOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; FLUORESCENCE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PROTEIN BINDING; SMOKING; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WAIST HIP RATIO;

ADULT; ARGININE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERY DISEASE; CORONARY VESSELS; DIABETES MELLITUS, TYPE 1; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MIDDLE AGED; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR CALCIFICATION; VASCULAR CELL ADHESION MOLECULE-1; VON WILLEBRAND FACTOR;

EID: 84885568545     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-149     Document Type: Article

References (56)

1. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006, 29(4):798-804. 10.2337/diacare.29.04.06.dc05-1433, 16567818.
2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820. 10.1038/414813a, 11742414.
3. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P, Stehouwer CD. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011, 34(2):442-447. 10.2337/dc10-1087, 3024364, 21270199.
4. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003, 21(1):3-12. 10.1097/00004872-200301000-00002, 12544424.
5. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105(7):816-822. 10.1161/hc0702.104183, 11854121.
6. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci 2005, 1043:676-680. 10.1196/annals.1333.077, 16037292.
7. Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, Teerlink T, Schrauwen P, Brownlee M, Stehouwer CD, Schalkwijk CG. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 2011, 286(2):1374-1380. 10.1074/jbc.M110.144097, 3020745, 21056979.
8. Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, Osawa T, Uchida K. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 1999, 274(26):18492-18502. 10.1074/jbc.274.26.18492, 10373458.
9. Thornalley PJ. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems-role in ageing and disease. Drug Metabol Drug Interact 2008, 23(1-2):125-150. 2649415, 18533367.
10. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005, 48(8):1590-1603. 10.1007/s00125-005-1810-7, 15988580.
11. Hwang JS, Shin CH, Yang SW. Clinical implications of N epsilon-(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes. Diabetes Obes Metab 2005, 7(3):263-267. 10.1111/j.1463-1326.2004.00398.x, 15811143.
12. Galler A, Muller G, Schinzel R, Kratzsch J, Kiess W, Munch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care 2003, 26(9):2609-2615. 10.2337/diacare.26.9.2609, 12941727.
13. Berg TJ, Dahl-Jorgensen K, Torjesen PA, Hanssen KF. Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care 1997, 20(6):1006-1008. 10.2337/diacare.20.6.1006, 9167115.
14. Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006, 70(1):218-224. 10.1038/sj.ki.5000330, 16723988.
15. Peters SA, Bakker M, den Ruijter HM, Bots ML. Added value of CAC in risk stratification for cardiovascular events: a systematic review. Eur J Clin Invest 2012, 42(1):110-116. 10.1111/j.1365-2362.2011.02555.x, 21644944.
16. Colhoun HM, Rubens MB, Underwood SR, Fuller JH. The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. J Am Coll Cardiol 2000, 36(7):2160-2167. 10.1016/S0735-1097(00)00986-4, 11127456.
17. Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 2003, 52(11):2833-2839. 10.2337/diabetes.52.11.2833, 14578303.
18. Nasrallah MM, El-Shehaby AR, Osman NA, Salem MM, Nassef A, El Din UA. Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients. Int Urol Nephrol 2012, 44(4):1193-1199. 10.1007/s11255-011-0007-x, 21643645.
19. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009, 46(6):572-580. 10.1159/000226225, 19571577.
20. Ren X, Shao H, Wei Q, Sun Z, Liu N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 2009, 37(3):847-854. 10.1177/147323000903700329, 19589269.
21. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, Chen D. Advanced glycation end-product Nepsilon-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012, 221(2):387-396. 10.1016/j.atherosclerosis.2012.01.019, 22305260.
22. Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA. Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol 2011, 33(3):250-259. 10.1159/000324693, 3064943, 21372560.
23. Cecil DL, Terkeltaub RA. Arterial calcification is driven by RAGE in Enpp1-/- mice. J Vasc Res 2011, 48(3):227-235. 10.1159/000318805, 2997448, 21099228.
24. Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(7):610-614. 10.1016/j.jchromb.2009.01.022, 19188098.
25. Hanssen NM, Engelen L, Ferreira I, Scheijen JL, Huijberts MS, van Greevenbroek MM, van der Kallen CJ, Dekker JM, Nijpels G, Stehouwer CD, et al. Plasma Levels of Advanced Glycation Endproducts N{epsilon}-(carboxymethyl)lysine, N{epsilon}-(carboxyethyl)lysine, and Pentosidine Are not Independently Associated With Cardiovascular Disease in Individuals With or Without Type 2 Diabetes: The Hoorn and CODAM Studies. J Clin Endocrinol Metab 2013, 98(8):E1369-1373. 10.1210/jc.2013-1068, 23780372.
26. van Eupen MG, Schram MT, Colhoun HM, Hanssen NM, Niessen HW, Tarnow L, Parving HH, Rossing P, Stehouwer CD, Schalkwijk CG. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia 2013, 56(8):1845-1855. 10.1007/s00125-013-2919-8, 23620061.
27. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15(4):827-832. 10.1016/0735-1097(90)90282-T, 2407762.
28. Dendukuri N, Chiu K, Brophy JM. Validity of electron beam computed tomography for coronary artery disease: asystematic review and meta-analysis. BMC Med 2007, 5:35. 10.1186/1741-7015-5-35, 2228285, 18036252.
29. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999, 130(6):461-470. 10.7326/0003-4819-130-6-199903160-00002, 10075613.
30. Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999, 42(3):351-357. 10.1007/s001250051162, 10096789.
31. Han Y, Randell E, Vasdev S, Gill V, Curran M, Newhook LA, Grant M, Hagerty D, Schneider C. Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes. Clin Biochem 2009, 42(7-8):562-569.
32. Hirata K, Kubo K. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes. Endocr J 2004, 51(6):537-544. 10.1507/endocrj.51.537, 15644571.
33. Fosmark DS, Torjesen PA, Kilhovd BK, Berg TJ, Sandvik L, Hanssen KF, Agardh CD, Agardh E. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 2006, 55(2):232-236. 10.1016/j.metabol.2005.08.017, 16423631.
34. Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000, 49(8):1030-1035. 10.1053/meta.2000.7738, 10954022.
35. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007, 50(7):1409-1417. 10.1007/s00125-007-0687-z, 17479244.
36. Conway B, Edmundowicz D, Matter N, Maynard J, Orchard T. Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. Diabetes Technol Ther 2010, 12(5):339-345. 10.1089/dia.2009.0152, 2883484, 20388043.
37. Orchard TJ, Lyons TJ, Cleary PA, Braffett BH, Maynard J, Cowie C, Gubitosi-Klug RA, Way J, Anderson K, Barnie A, et al. The Association of Skin Intrinsic Fluorescence With Type 1 Diabetes Complications in the DCCT/EDIC Study. Diabetes Care 2013, 36(10):3146-3153. 10.2337/dc12-2661, 23813757.
38. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 1989, 264(36):21597-21602.
39. Engelbertsen D, Anand DV, Fredrikson GN, Hopkins D, Corder R, Shah PK, Lahiri A, Nilsson J, Bengtsson E. High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes. J Intern Med 2012, 271(1):82-89. 10.1111/j.1365-2796.2011.02411.x, 21668821.
40. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008, 118(1):183-194. 10.1172/JCI32703, 2129235, 18079965.
41. Costacou T, Lopes-Virella MF, Zgibor JC, Virella G, Otvos J, Walsh M, Orchard TJ. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The pittsburgh epidemiology of diabetes complications study. J Diabetes Complications 2005, 19(4):183-193. 10.1016/j.jdiacomp.2005.01.003, 15993351.
42. Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A, Matsuhisa M, Kosugi K, Nishikawa N, Kajimoto Y, et al. Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 2002, 25(8):1432-1438. 10.2337/diacare.25.8.1432, 12145246.
43. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB prospective complications study. Diabetologia 2005, 48(2):370-378. 10.1007/s00125-004-1628-8, 15692810.
44. Tada Y, Yano S, Yamaguchi T, Okazaki K, Ogawa N, Morita M, Sugimoto T. Advanced glycation end products-induced vascular calcification is mediated by oxidative stress: functional roles of NAD(P)H-oxidase. Horm Metab Res 2013, 45(4):267-272.
45. Wei Q, Ren X, Jiang Y, Jin H, Liu N, Li J. Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress. BMC Cardiovasc Disord 2013, 13:13. 10.1186/1471-2261-13-13, 3626911, 23497312.
46. Chen J, Song M, Yu S, Gao P, Yu Y, Wang H, Huang L. Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress. Mol Cell Biochem 2010, 335(1-2):137-146.
47. Li H, Zhang X, Guan X, Cui X, Wang Y, Chu H, Cheng M. Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells. Cardiovasc Diabetol 2012, 11:46. 10.1186/1475-2840-11-46, 3403843, 22545734.
48. Ueno H, Koyama H, Fukumoto S, Tanaka S, Shoji T, Emoto M, Tahara H, Inaba M, Kakiya R, Tabata T, et al. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism 2011, 60(4):453-459. 10.1016/j.metabol.2010.04.001, 20494372.
49. Palombo C, Kozakova M, Morizzo C, Gnesi L, Barsotti MC, Spontoni P, Massart F, Salvi P, Balbarini A, Saggese G, et al. Circulating endothelial progenitor cells and large artery structure and function in young subjects with uncomplicated type 1 diabetes. Cardiovasc Diabetol 2011, 10:88. 10.1186/1475-2840-10-88, 3198903, 21981808.
50. Gossl M, Modder UI, Atkinson EJ, Lerman A, Khosla S. Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol 2008, 52(16):1314-1325. 10.1016/j.jacc.2008.07.019, 2613163, 18929243.
51. Eghbali-Fatourechi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL, Khosla S. Circulating osteoblast-lineage cells in humans. N Engl J Med 2005, 352(19):1959-1966. 10.1056/NEJMoa044264, 15888696.
52. Flammer AJ, Gossl M, Widmer RJ, Reriani M, Lennon R, Loeffler D, Shonyo S, Simari RD, Lerman LO, Khosla S, et al. Osteocalcin positive CD133+/CD34-/KDR + progenitor cells as an independent marker for unstable atherosclerosis. Eur Heart J 2012, 33(23):2963-2969. 10.1093/eurheartj/ehs234, 22855739.
53. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, Schwartz RS. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 1998, 31(1):126-133. 10.1016/S0735-1097(97)00443-9, 9426030.
54. Edmonds ME. Medial arterial calcification and diabetes mellitus. Z Kardiol 2000, 89(Suppl 2):101-104.
55. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331(7):417-424. 10.1056/NEJM199408183310701, 7880233.
56. Muris DM, Houben AJ, Schram MT, Stehouwer CD. Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2012, 32(12):3082-3094. 10.1161/ATVBAHA.112.300291, 23042819.